Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism

The human gut microbiota metabolizes the Parkinson’s disease medication Levodopa (L-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Rekdal, Vayu Maini, Bess, Elizabeth N., Bisanz, Jordan E., Turnbaugh, Peter J., Balskus, Emily P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Article Summary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745125/
https://www.ncbi.nlm.nih.gov/pubmed/31196984
http://dx.doi.org/10.1126/science.aau6323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745125/
https://www.ncbi.nlm.nih.gov/pubmed/31196984
http://dx.doi.org/10.1126/science.aau6323

Ejemplares similares